Management of relapse after allo-SCT for AML and the role of second transplantation
- 26 October 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 44 (12), 769-777
- https://doi.org/10.1038/bmt.2009.300
Abstract
Relapse after allo-SCT for AML carries very poor prognosis. Second allo-SCT, although curative, is not an appropriate treatment option for a large number of relapsing patients (only 2–20% patients receive a second allo-SCT), and efforts to increase the number of patients who may benefit from a second allo-SCT are ongoing. In addition, understanding the varied biological processes that are operative in disease relapse has encouraged the development of novel therapies, and could be beneficial to patients who are currently managed conservatively with supportive care for relapsed disease. Incorporating novel combinations of drugs with immunomodulation, although theoretically attractive, should be tested in the setting of clinical trials. In this review, we discuss the currently available approaches for relapsed AML after allo-SCT.Keywords
This publication has 67 references indexed in Scilit:
- Acute Myeloid Leukemia in the ElderlySeminars in Oncology, 2008
- Costs of Allogeneic Hematopoietic Cell Transplantation with High-Dose RegimensTransplantation and Cellular Therapy, 2008
- Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working PartyJournal of Clinical Oncology, 2007
- Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI aloneBlood, 2007
- A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemiasBlood, 2007
- Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplantNature Clinical Practice Oncology, 2007
- Clofarabine: Past, present, and futureLeukemia & Lymphoma, 2007
- Extramedullary sites of leukemia relapse after transplantLeukemia & Lymphoma, 2006
- Outcomes of patients with acute leukaemia who relapsed after reduced‐intensity stem cell transplantation from HLA‐identical or one antigen‐mismatched related donorsBritish Journal of Haematology, 2005
- Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapyBone Marrow Transplantation, 1997